Articles by Amy Ritter - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Amy Ritter

Amy Ritter


Amy Ritter is Scientific Editor, BioPharm International and Pharmaceutical Technology. Amy Ritter joined the editorial staff of BioPharm International and Pharmaceutical Technology in 2011. She received her BA in Biology from Boston University, and holds a PhD in Neurobiology from SUNY at Stony Brook. Before joining Advanstars Pharm Sciences group, she worked in the preclinical pharmacology group at Merck Research Labs, and is the author of numerous peer-reviewed scientific publications.

Articles
AstraZeneca Announces an Additional 2300 Layoffs
March 22, 2013

AstraZeneca announced further downsizing in response to an expected period of declining revenues in the face of patent expirations. The company will eliminate 2300 positions in sales and general administration.

AstraZeneca to Cut 1600 Positions in R&D Reorganization
March 18, 2013

AstraZeneca announced that it will consolidate its R&D capabilities into three centers located in Cambridge, UK; Gaithersburg, MD in the US; and M?lndal, Sweden. The reorganization will result in a net loss of 1600 position, mostly in the US and the UK.

INTERPOL and Pharma Collaborate to Fight Counterfeiting
March 12, 2013

INTERPOL and 29 of the world's largest pharmaceutical companies have joined forces in an initiative to battle counterfeit drugs.

Mylan Acquires Generic Injectables Unit From Strides Arcolab
March 5, 2013

Mylan announced that it has signed an agreement to acquire the generic injectables unit Agila Specialties from Strides Arcolab for $1.6 billion in cash.

Roche/Genentech Win FDA Approval for Antibody-Drug Conjugate
February 22, 2013

FDA approved Roche?s antibody-drug conjugate, Kadcyla (trastuzumab emtansine or T-DM1), for the treatment of people with HER2-positive metastatic breast cancer.

BARDA Continues to Support Protein Sciences' Cell-Based Vaccine Programs
February 19, 2013

Protein Sciences announced that the Biomedical Advanced Research and Development Authority (BARDA) will continue to support the company?s influenza vaccines program.

FDA Lists Guidance Documents Planned for 2013
February 5, 2013

FDA has released a list of more than 50 guidance documents planned for 2013.

ADVERTISEMENT

ADVERTISEMENT

Click here